Leukaemia and Paediatric Haematology Disorders

Research Program

Paediatric Cancer

Where we are

SJD Barcelona Children's Hospital

How to reach us

Related websites

Our group carries out translational research with the aim of applying the advances made in biological diagnosis to healthcare practice and the use of the most innovative treatments in paediatric patients with blood disorders. Since its creation in 2012, our group has obtained uninterrupted funding for competitive and non-competitive calls for public and private aid.

We participate as a clinical group associated with the Hereditary Cancer and Related Syndromes Group in the Centre for Biomedical Network Research on Rare Diseases (CIBERER). The Hereditary Red Blood Cell Disorders Unit, which is part of both SJD Barcelona Children's Hospital and Hospital de la Santa Creu i Sant Pau, will shortly be recognised as a Reference Centre-Service Unit (RCSU).

We have been a consolidated AGAUR research group (Government of Catalonia, references 2014 SGR 1398 and 2017 SGR 1672) since 2014.

Research lines

  1. Acute lymphoblastic leukaemia (ALL).
  2. Acute myeloblastic leukaemia (AML).
  3. Bone marrow failure and myelodysplastic syndromes.
  4. Red blood cell disorders.
  5. Alterations in haemostasis.
  6. Immunotherapy and cell therapy.
  7. Prevention of toxicity secondary to leukaemia treatment.

Scientific objectives

  1. To consolidate our group as a CIBER associated clinical group and define the current situation of paediatric haematology diseases in the context of those considered as "rare diseases".
  2. To promote cooperative strategies to advance biological diagnosis and follow-up of minimal residual disease (MRD) in cases of acute leukaemias and other paediatric haematology disorders. To design and implement new techniques and internal/external quality controls.
  3. To analyse new biomarkers of potential diagnostic, prognostic and therapeutic utility in high-risk paediatric leukaemias.
  4. To promote the applicability of new therapies in paediatric patients by conducting clinical trials. To consolidate the experience of our group in the use of cell therapy with combination antiretroviral therapy (cART) and haematopoietic progenitor transplantation.
  5. To study the biological and clinical factors that could help prevent or alleviate toxicity secondary to leukaemia therapy.
  6. To apply photonics to the diagnosis and monitoring of red blood cell disorders.
  7. To study the risk factors associated with chemotherapy-induced thrombosis in paediatric ALL and establish preventive measures.
  8. To establish genomic precision diagnosis using next-generation sequencing techniques to different paediatric haematology disorders.

Area/Field of expertise

We conduct translational research aimed at the rapid "bench-to-bedside" application of diagnostic and therapeutic innovations relevant to leukaemia and other haematology disorders. Our group includes haematologists, paediatric haematology-oncologists, biologists and lab technicians, with recognised expertise in the diagnosis and treatment of children with haematology disorders. With this multidisciplinary team, we can provide a comprehensive approach to the real problems of patients and conduct research that is readily transmitted to clinical practice.

Since its creation, our group has established itself within the main clinical and biological coordination positions in the area of paediatric haematology disorders. This has enabled us to represent the Spanish group in major international cooperative groups and participate in national and international cooperation projects.

Over the past few years, we have incorporated diagnostic and therapeutic tools and consolidated the harvesting of blood samples in our biobank. This has led to the establishing of the hospital as a reference centre for research into childhood leukaemia and other blood disorders. We deploy various methodologies including complete biological diagnosis and close monitoring of minimal residual disease in acute leukaemia (morphology, flow cytometry, molecular biology, including next-generation sequencing, lymphoid clonality testing, etc.). The incorporation of global haemostasis assays, such as the thrombin generation assay, will enable us to establish normal values and standardise their use in the paediatric population.

This year, the integrated HSJD-HSP unit was granted RSCU accreditation in hereditary RBC disorders.

Group members

Last Publications

More Publications


Project name:
New approaches for the identification and functional characterization of prognostic genetic biomarkers in inherited childhood myelodysplastic/acute leukemia syndromes Acronym: GEMMA
Albert Català Temprano
Funding entities:
Fundació La Marató de TV3
Starting - finishing date:
2021 - 2024
Project name:
Nuevas técnicas para la detección precisa de los reordenamientos del gen MLL y conseguir un mejor seguimiento de la enfermedad residual mínima en pacientes pediátricos con leucemia aguda
Mireia Camós Guijosa
Funding entities:
Fundación CRIS de investigación para vencer el cáncer
Starting - finishing date:
2021 - 2023
Project name:
Implementación de la estrategia de tratamiento Alltogether para leucemia linfoblástica aguda pediátrica en España.
Mireia Camós Guijosa, Susana Rives Solà
Funding entities:
Fundación Uno entre Cien Mil
Starting - finishing date:
2021 - 2022
More projects


  • Estudi del perfil d'expressió de les histones deacetilasa (HDAC) en pacients pediàtrics amb leucèmia aguda
    Vega García, Nerea
  • Análisis del valor pronóstico del perfil de expresión génica en la leucemia mieloblástica aguda de riesgo citogenético intermedio según la opción terapéutica post-remisión
    Torrebadell Burriel, Montserrat
  • Caracterizació de les alteracions moleculars deFLT3 en pacients pediàtrics afectes de leucèmia aguda. Correlació amb l’activitat i expressió dels transportadors de fàrmacs derivats de nucleòsids
    Català Temprano, Albert
More Theses